Johnson & Johnson (NYSE: JNJ) has a diverse healthcare business, and investors often look to it as a safe dividend stock to invest in for the long term. The company's growth is often in the single ...
Fast Company on MSN9d
Johnson & Johnson ketamine-derived nasal spray gets FDA approval for depression, but JNJ stock dips on earningsSpravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...
The Food and Drug Administration on Tuesday approved Johnson & Johnson's nasal spray to be used alone in adults with a major ...
The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...
Spravato, okayed for stand-alone use among adults, is the first such therapy for major depressive disorder (MDD) that is ...
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first ...
One-third of folks with major depressive disorder experience treatment-resistant depression (TRD), a condition that makes it ...
Johnson & Johnson has announced that the U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal ...
On Tuesday, the FDA approved Johnson & Johnson’s (NYSE:JNJ) supplemental New Drug Application for Spravato (esketamine) CIII ...
Already on its way to becoming a blockbuster drug, Johnson & Johnson’s Spravato has received another potential boost as the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback